Drug Trial Radar · NCT05363384
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 11, 2022
Primary completion
Jun 21, 2022
Study completion Jul 12, 2022
Sponsor
- Lead sponsor
- CelltrionIndustry
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, open, single-dose, crossover-design, phase 1, single-center study to evaluate bioequivalence after co-administration of ALO and MET XR or administration of CT-L01 in healthy volunteers.
Conditions
- Healthy
Interventions
CT-L01Drug
FDC tablet, single dose, oral administration
Alogliptin Benzoate 25 mgDrug
Alogliptin Benzoate 25 mg, oral administration
Metformin HCl XR 1,000 mgDrug
Metformin HCl XR 1,000 mg, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUClast (Area under the plasma concentration-time curve)Time frame: Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours
- Cmax (Peak Plasma Concentration)Time frame: Pre-dose(0.00), 0.25, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00, and 72.00 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chungnam National University Hospital
Daejeon, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.